CellResearch Corporation launches scientifically formulated skincare line in Thailand, enhanced with the benefits of original stem-cell technology
Singapore-based bio-tech company CellResearch Corporation is channeling 10-years of stem-cell research and technology into CALECIM® Professional, a skincare line that is available to consumers seeking younger-looking and healthier skin.
The range of advanced cosmetic skin care, that is only available through physician-dispensed channels, draws on its parent company’s patented stem-cell knowledge. CellResearch Corporation is the first company in the world to discover a rich source of stem cells in the umbilical cord lining. These cells are currently being developed as a platform to treat a wide-range of diseases including those of the brain, heart, cornea, and skin.
“I believe there is great synergistic benefits from our stem-cell research that can be applied to a skin care beauty product which is accessible to everyone,” says Gavin Tan, Chief Executive Officer of CellResearch Corporation. “While umbilical cord lining cells have been making waves world-wide in the area of medical science, we would like for the general consumer to experience a part of our technology as well. This is why we decided to introduce CALECIM® Professional to the market.”
CALECIM® Professional is a protein-rich formulation of nutrients that has been created in conditions that allow the renewal properties from umbilical cord extract to nurture the skin. This enhancement of the skin’s environment allows for it to act younger and look younger.
CALECIM® Professional has been rapidly adopted by many doctors in their aesthetic in-clinic treatments because of its extraordinary efficacy and proven clinical results that target the many symptoms of aging skin. The CALECIM® Professional anti-aging system acts as a perfect adjunct to many in-clinic procedures such as laser treatments, IPL, dermabrasion, iontophoresis, microneedling, and chemical peels. It is also able to soothe and reduce skin discomfort incurred during clinical treatments while enhancing the overall skin condition.
Enhanced results from in-clinic procedures can be prolonged with the brand’s targeted at-home maintenance regime. Clinical observations of CALECIM® Professional’s Multi-Action Cream reveal that results can be observed in just two weeks.
“I have just concluded a 4 week trial using CALECIM® Professional Multi-Action Cream, and have been quite impressed with the changes in my patient’s skin, even after only 2 weeks of use. In addition to an improved overall complexion, I have observed increased skin tone and skin fullness resulting in a lifting effect, a tighter jawline, elevated eyebrows, and enhanced facial definition. Our results have been consistent across a range of skin types and patient ages, with high patient satisfaction. In fact, most of the patients have asked to continue using CALECM® Professional Multi-Action Cream even after the trial formally ended.” says Ziv M. Peled, MD, a board-certified plastic surgeon with a practice in San Francisco.
CALECIM® Professional is available through selected dermatologists, plastic surgeons and aesthetic doctors’ clinics. During the official press conference in Bangkok, senior members of Calecim flew in to showcase a demo with celebrity guests and audience. Guests of honor include host and music industry extraordinaire Salinee Panyarachun and renowned singer Tanachai Ujjin (Pod) from Modern Dog.
For more information, visit http://calecimprofessional.com/
About CellResearch Corporation Pte. Ltd.
Founded in Singapore in 2002 by a group of clinician scientists and investors, CellResearch is the pioneer and global leader in Cord Lining Stem Cells for Stem Cell Regenerative Medicine and Therapy. Both an inventor and market leader in this space, CellResearch is at its core a Cord Lining Stem Cell Technology Asset Manager, with its main business lines comprising the banking of Cord Lining Stem Cells, development of cosmetic skincare in the form of their product, CALECIM® Professional, and advanced wound care, through their CorLinEx™ developments.
The company also owns one of the world's largest private skin, scar and keloid cell libraries, which provides high quality primary cell strains, culture media and research service support to researchers and corporations worldwide. A company valuation of S$730 million as of 2015 can be attributed to the impressive pace at which CellResearch has worked to obtain a vast spectrum of patents in over 35 countries worldwide for their innovations and products.
For more information, visit http://www.cellresearchcorp.com/
